U Ottawa-Led International Team Uncovers Key Breakthrough in Nerve-to-Muscle Communication

In a groundbreaking revelation that deepens our understanding of neuromuscular communication, an international research team led by Dr. John Baenziger from the University of Ottawa’s Faculty of Medicine has provided an unprecedented atomic-level depiction of how nerve signals activate at the neuromuscular junction. This junction—a highly specialized synapse connecting motor neurons to skeletal muscle fibers—functions as the critical interface for muscle control. The team’s pioneering use of advanced single-molecule techniques has unlocked a detailed view of the activation pathway of the nicotinic acetylcholine receptor (nAChR), offering insights that could revolutionize therapeutic approaches for neuromuscular disorders.

The study, published in the esteemed journal Science, leveraged sophisticated structural biology tools to capture a series of conformational states of the nAChR with atomic resolution. This receptor, pivotal in translating chemical signals from neurons into muscle contractions, has long been a subject of intense research due to its fundamental role in motor function and its implication in various neuromuscular diseases. Dr. Baenziger’s team identified and characterized a previously elusive intermediate conformation, termed the “primed” state, which bridges the gap between the receptor’s resting unliganded form and its fully activated state.

This primed state represents an essential transitional phase that underscores the dynamic nature of neuromuscular signaling. Historically, models of receptor activation have assumed a concerted conformational change—a synchronized shift wherein all subunits of the pentameric receptor move simultaneously to achieve activation. However, the research challenges this decades-old dogma, revealing instead an asynchronous activation mechanism. This nuanced understanding shows that distinct domains of the receptor undergo structural rearrangements sequentially, which adds an additional layer of complexity to receptor dynamics and functional modulation.

Central to this discovery was the use of cryo-electron microscopy (cryo-EM) alongside single-molecule fluorescence resonance energy transfer (smFRET) approaches. By globally aligning receptor conformations based on their transmembrane M1-M3 helices, the researchers were able to visualize subtle extracellular domain movements relative to the transmembrane segments as the receptor transitioned between states. These detailed structural snapshots elucidate the stepwise nature of receptor activation, from unliganded to monoliganded and finally to the diliganded state, confirming the presence and nature of the primed intermediate.

Beyond the fundamental mechanistic insights, this revelation has profound implications for neuropathologies associated with compromised synaptic transmission. The asynchronous movement paradigm redefines how mutations associated with congenital myasthenic syndromes—disorders marked by muscle weakness due to defective neuromuscular transmission—might alter receptor function. By distinguishing the temporal order of conformational changes, researchers can better predict the functional consequences of pathogenic mutations, which may selectively disrupt early or late phases of activation.

Moreover, the findings open new avenues for rational drug design. Therapeutics targeting the nAChR have traditionally been developed under the assumption of a wholly concerted transition. Now, drugs can be engineered with higher precision to stabilize or destabilize specific intermediate states, including the primed conformation, to fine-tune receptor activity. This precision could culminate in more effective treatments for a spectrum of neuromuscular disorders, optimizing efficacy while minimizing side effects.

Significantly, the nicotinic acetylcholine receptor is a member of an extensive family of pentameric ligand-gated ion channels that mediate synaptic transmission not only in muscle but throughout the nervous system, including the brain. Consequently, insights gleaned from this study resonate beyond the neuromuscular junction, potentially informing our understanding of synaptic function in central nervous system pathologies such as neurodegenerative diseases and cognitive disorders.

The research team’s multidisciplinary collaboration was integral to this breakthrough. Dr. Baenziger’s laboratory at uOttawa spearheaded the structural studies, while Drs. Hugues Nury and Elefterios Zarkadas at the Institute of Structural Biology in Grenoble contributed complementary cryo-EM expertise. Furthermore, Dr. Corrie daCosta from the University of Ottawa’s Faculty of Science enhanced the project with cutting-edge single-molecule functional analyses, integrating structural and dynamic data.

The foundational work was carried out by lead author Dr. Mackenzie Thompson, whose doctoral studies in Dr. Baenziger’s lab transitioned into postdoctoral research at the University of California, Berkeley. This transition facilitated ongoing investigation into the receptor’s functional dynamics, including structural characterization of variants harboring disease-causing mutations and their pharmacological responses.

Looking ahead, the research team aims to exploit the newly elucidated structural templates to deconvolute the impact of pathological mutations on receptor activation. By comparing altered receptor conformations in the presence and absence of candidate pharmaceutical agents, they hope to identify compounds capable of restoring normal function or modulating receptor activity beneficially.

Ultimately, this pioneering study reframes long-standing assumptions about receptor conformational dynamics during synaptic transmission, offering a granular view of the molecular choreography underlying the translation of neural signals into muscular action. Dr. Baenziger emphasizes how these discoveries enrich our collective understanding across neuroscience and muscle biology disciplines, setting the stage for innovative translational applications that could significantly improve outcomes for patients suffering from neuromuscular diseases.

News Publication Date: 2-Oct-2025

Web References:

• DOI link